Protocol Ledger

NCT05600426 · Phase III · TERMINATED

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Interventional Phase III clinical trial protocol NCT05600426 sponsored by Boston Children's Hospital in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-25 Enrollment: 53 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05600426
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)53 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05600426
Protocol FieldVerified Registry Value
NCT IdentifierNCT05600426
Consolidated Lead SponsorBoston Children's Hospital
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment53 participants (ACTUAL)
Registered Start Date2023-01-25
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boston Children's Hospital across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI